Myomo (MYO) Capital Expenditures Growth (1y) (2018 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 27.22% |
| 10 | Myomo | 44.63 Mn | 26.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 228.30% |
| Jun 30, 2025 | 1,515.24% |
| Dec 31, 2024 | 2,616.72% |
| Sep 30, 2024 | 492.88% |
| Jun 30, 2024 | 697.20% |
| Mar 31, 2024 | 32.66% |
| Dec 31, 2023 | 835.45% |
| Sep 30, 2023 | 843.04% |
| Jun 30, 2023 | -71.64% |
| Mar 31, 2023 | -9.61% |
| Dec 31, 2022 | -85.86% |
| Sep 30, 2022 | -89.55% |
| Jun 30, 2022 | -74.01% |
| Mar 31, 2022 | 12.12% |
| Dec 31, 2021 | 54.84% |
| Sep 30, 2021 | 144.84% |
| Mar 31, 2021 | 464.72% |
| Dec 31, 2020 | 12.59% |
| Sep 30, 2020 | 567.54% |
| Mar 31, 2020 | 45.78% |
| Dec 31, 2019 | 44.57% |
| Sep 30, 2019 | -90.65% |
| Jun 30, 2019 | 78.42% |
| Mar 31, 2019 | -91.68% |
| Dec 31, 2018 | -84.11% |
| Sep 30, 2018 | 1,491.18% |
| Jun 30, 2018 | 2,149.39% |
| Mar 31, 2018 | 1,426.90% |